268 related articles for article (PubMed ID: 23361564)
1. Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology.
Rice T; Zheng S; Decker PA; Walsh KM; Bracci P; Xiao Y; McCoy LS; Smirnov I; Patoka JS; Hansen HM; Hsuang G; Wiemels JL; Tihan T; Pico AR; Prados MD; Chang SM; Berger MS; Caron A; Fink S; Kollmeyer T; Rynearson A; Voss J; Kosel ML; Fridley BL; Lachance DH; Eckel-Passow JE; Sicotte H; O'Neill BP; Giannini C; Wiencke JK; Jenkins RB; Wrensch MR
Neuro Oncol; 2013 May; 15(5):535-41. PubMed ID: 23361564
[TBL] [Abstract][Full Text] [Related]
2. Adult IDH wild-type lower-grade gliomas should be further stratified.
Aibaidula A; Chan AK; Shi Z; Li Y; Zhang R; Yang R; Li KK; Chung NY; Yao Y; Zhou L; Wu J; Chen H; Ng HK
Neuro Oncol; 2017 Oct; 19(10):1327-1337. PubMed ID: 28575485
[TBL] [Abstract][Full Text] [Related]
3. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N
Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423
[TBL] [Abstract][Full Text] [Related]
4. Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci.
Labreche K; Kinnersley B; Berzero G; Di Stefano AL; Rahimian A; Detrait I; Marie Y; Grenier-Boley B; Hoang-Xuan K; Delattre JY; Idbaih A; Houlston RS; Sanson M
Acta Neuropathol; 2018 May; 135(5):743-755. PubMed ID: 29460007
[TBL] [Abstract][Full Text] [Related]
5. IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation.
Oktay Y; Ülgen E; Can Ö; Akyerli CB; Yüksel Ş; Erdemgil Y; Durası IM; Henegariu OI; Nanni EP; Selevsek N; Grossmann J; Erson-Omay EZ; Bai H; Gupta M; Lee W; Turcan Ş; Özpınar A; Huse JT; Sav MA; Flanagan A; Günel M; Sezerman OU; Yakıcıer MC; Pamir MN; Özduman K
Sci Rep; 2016 Jun; 6():27569. PubMed ID: 27282637
[TBL] [Abstract][Full Text] [Related]
6. Molecular Classification of Gliomas is Associated with Seizure Control: A Retrospective Analysis.
Easwaran TP; Lancki N; Henriquez M; Vortmeyer AO; Barbaro NM; Scholtens DM; Ahmed AU; Dey M
Neuromolecular Med; 2021 Jun; 23(2):315-326. PubMed ID: 33206320
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
[TBL] [Abstract][Full Text] [Related]
8. Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies.
Di Stefano AL; Enciso-Mora V; Marie Y; Desestret V; Labussière M; Boisselier B; Mokhtari K; Idbaih A; Hoang-Xuan K; Delattre JY; Houlston RS; Sanson M
Neuro Oncol; 2013 May; 15(5):542-7. PubMed ID: 23161787
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
[TBL] [Abstract][Full Text] [Related]
10. 1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas.
Zhang Y; Xie Y; He L; Tang J; He Q; Cao Q; Cui L; Guo W; Hua K; Dimberg A; Wang L; Zhang L
Cell Oncol (Dordr); 2021 Feb; 44(1):193-204. PubMed ID: 32915415
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
12. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
Labussière M; Di Stefano AL; Gleize V; Boisselier B; Giry M; Mangesius S; Bruno A; Paterra R; Marie Y; Rahimian A; Finocchiaro G; Houlston RS; Hoang-Xuan K; Idbaih A; Delattre JY; Mokhtari K; Sanson M
Br J Cancer; 2014 Nov; 111(10):2024-32. PubMed ID: 25314060
[TBL] [Abstract][Full Text] [Related]
14. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.
Zhang B; Chang K; Ramkissoon S; Tanguturi S; Bi WL; Reardon DA; Ligon KL; Alexander BM; Wen PY; Huang RY
Neuro Oncol; 2017 Jan; 19(1):109-117. PubMed ID: 27353503
[TBL] [Abstract][Full Text] [Related]
15. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.
Juratli TA; Peitzsch M; Geiger K; Schackert G; Eisenhofer G; Krex D
Neuro Oncol; 2013 Jun; 15(6):682-90. PubMed ID: 23410661
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.
Chan AK; Yao Y; Zhang Z; Chung NY; Liu JS; Li KK; Shi Z; Chan DT; Poon WS; Zhou L; Ng HK
Mod Pathol; 2015 Feb; 28(2):177-86. PubMed ID: 25081751
[TBL] [Abstract][Full Text] [Related]
18. Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis.
Walsh KM; Rice T; Decker PA; Kosel ML; Kollmeyer T; Hansen HM; Zheng S; McCoy LS; Bracci PM; Anderson E; Hsuang G; Wiemels JL; Pico AR; Smirnov I; Molinaro AM; Tihan T; Berger MS; Chang SM; Prados MD; Lachance DH; Sicotte H; Eckel-Passow JE; Wiencke JK; Jenkins RB; Wrensch MR
Neuro Oncol; 2013 Aug; 15(8):1041-7. PubMed ID: 23733245
[TBL] [Abstract][Full Text] [Related]
19. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of gliomas in patients with somatic IDH mosaicism.
Bonnet C; Thomas L; Psimaras D; Bielle F; Vauléon E; Loiseau H; Cartalat-Carel S; Meyronet D; Dehais C; Honnorat J; Sanson M; Ducray F
Acta Neuropathol Commun; 2016 Mar; 4():31. PubMed ID: 27036230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]